The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States

BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive, and fatal disease associated with considerable overall clinical and economic burden. Although the direct health care costs of PAH have been well described, there are few data regarding indirect costs and productivity loss asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogbomo, Adesuwa, Tsang, Yuen, Mallampati, Rajesh, Panjabi, Sumeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372985/
https://www.ncbi.nlm.nih.gov/pubmed/35621726
http://dx.doi.org/10.18553/jmcp.2022.28.6.608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372985/
https://www.ncbi.nlm.nih.gov/pubmed/35621726
http://dx.doi.org/10.18553/jmcp.2022.28.6.608

Ejemplares similares